Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Sylvie Carnoy"'
Autor:
David Beauvais, Olivier Hequet, Valérie Mialou, Jean-Louis Beaumont, Sylvie Carnoy, Justina Kanold, Caroline Ballot, Christian Chabannon, Nathalie Parquet, Tarik Kanouni, Gandhi Damaj, Ibrahim Yakoub-Agha, Loïc Reppel
Publikováno v:
Bulletin du Cancer
Bulletin du Cancer, 2021, 108 (3), pp.295-303. ⟨10.1016/j.bulcan.2020.11.014⟩
Bulletin du Cancer, John Libbey Eurotext, 2021, 108 (3), pp.295-303. ⟨10.1016/j.bulcan.2020.11.014⟩
Bulletin du Cancer, 2021, 108 (3), pp.295-303. ⟨10.1016/j.bulcan.2020.11.014⟩
Bulletin du Cancer, John Libbey Eurotext, 2021, 108 (3), pp.295-303. ⟨10.1016/j.bulcan.2020.11.014⟩
Resume Les cellules T a recepteur antigenique chimerique (CAR T-cells) sont une nouvelle classe de traitements anticancereux produits en manipulant genetiquement des lymphocytes T autologues ou allogeniques afin de generer l’expression d’un recep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::996c1f692adc313e60da19694b74cfa3
https://hal.science/hal-03211959/document
https://hal.science/hal-03211959/document
Autor:
Remy Dulery, Jean-Louis Beaumont, Agnes Perrin, Sylvie Carnoy, Cécile Gibault-Joffe, Virginie Ader, Nathalie Contentin, Sophie Plaza-Milhe, Nathalie Fegueux, Philippe Lewalle, Christine Giraud, Marie-Noëlle Lacassagne, Thi Ngoc Phuong Huynh, Alexandre Carpentier, Agnès Bonnin, Marie-Agnès Guerout-Verite, Ibrahim Yakoub-Agha
Publikováno v:
Bulletin du Cancer
Bulletin du Cancer, John Libbey Eurotext, 2020, 107, pp.S193-S201. ⟨10.1016/j.bulcan.2020.10.001⟩
Bulletin du Cancer, 2020, 107, pp.S193-S201. ⟨10.1016/j.bulcan.2020.10.001⟩
Bulletin du Cancer, John Libbey Eurotext, 2020, 107, pp.S193-S201. ⟨10.1016/j.bulcan.2020.10.001⟩
Bulletin du Cancer, 2020, 107, pp.S193-S201. ⟨10.1016/j.bulcan.2020.10.001⟩
International audience; CAR T-cells are anti-cancer immunocellular therapy drugs that involve reprogramming the patient's T-cells using a transgene encoding a chimeric antigen receptor (CAR). Although CAR T-cells are cellular therapies, the organizat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8144ee05c2d384b866352c6c817959e9
https://hal.archives-ouvertes.fr/hal-03493426
https://hal.archives-ouvertes.fr/hal-03493426
Autor:
Sylvie, Carnoy, Jean-Louis, Beaumont, Tarik, Kanouni, Nathalie, Parquet, David, Beauvais, Olivier, Hequet, Justina, Kanold, Caroline, Ballot, Valérie, Mialou, Loïc, Reppel, Gandhi, Damaj, Ibrahim, Yakoub-Agha, Christian, Chabannon
Publikováno v:
Bulletin du cancer. 108(3)
Chimeric antigen receptor (CAR) T-cells are a new class of cancer treatments manufactured through autologous or allogeneic T cells genetic engineering to induce CAR expression directed against a membrane antigen present at the surface of malignant ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::77b3c5f215273ececff6155624c696e3
https://pubmed.ncbi.nlm.nih.gov/33610284
https://pubmed.ncbi.nlm.nih.gov/33610284
Autor:
Rémy, Duléry, Marie-Noëlle, Lacassagne, Christine, Giraud, Virginie, Ader, Jean-Louis, Beaumont, Sylvie, Carnoy, Alexandre, Carpentier, Nathalie, Fegueux, Cécile, Gibault-Joffe, Marie-Agnès, Guerout-Verite, Thi Ngoc Phuong, Huynh, Philippe, Lewalle, Agnès, Perrin, Sophie, Plaza-Milhe, Agnès, Bonnin, Ibrahim, Yakoub-Agha, Nathalie, Contentin
Publikováno v:
Bulletin du cancer. 107(12S)
CAR T-cells are anti-cancer immunocellular therapy drugs that involve reprogramming the patient's T-cells using a transgene encoding a chimeric antigen receptor (CAR). Although CAR T-cells are cellular therapies, the organization for manufacturing an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2ad1acd5df08d2ba3dda40eaf5bf98aa
https://pubmed.ncbi.nlm.nih.gov/33187683
https://pubmed.ncbi.nlm.nih.gov/33187683